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Abstract: The review by Shander et al. in this issue of the journal highlights the progress made in trans-
fusion medicine since the 1980s, including the tremendous decrease in the risk of transfusion-transmitted
infections (TTIs) and the development of remarkably similar (and uniformly restrictive) transfusion
guidelines by five major professional societies and the American Association of Blood Banks1. These
guidelines aim at reducing the number of a patient’s allogeneic donor exposures as much as possible,
by administering transfusion only when proven (rather than postulated) benefit can be expected from
the transfusion. Proven benefit, exemplified by a red-blood-cell (RBC) transfusion to a stable and non-
bleeding patient triggered by a haemoglobin of 7 g/dL, is based on findings from randomised controlled
trials (RCTs) using clinical endpoints2. (...)
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Abstract
The  review by  Shander  et al.   in  this  issue  of  the  journal  highlights  the  progress  made   in  transfusion
medicine  since  the  1980s,   including  the  tremendous  decrease   in  the  risk  of  transfusion‐transmiƩed
infecƟons   (TTIs)  and   the  development  of   remarkably  similar   (and  uniformly   restricƟve)   transfusion
guidelines  by five  major professional  socieƟes  and  the  American AssociaƟon  of Blood  Banks1.  These
guidelines  aim  at   reducing   the  number  of  a  patient's  allogeneic  donor  exposures  as  much  as

















the  1980s,   including   the   tremendous  decrease   in   the   risk  of   transfusion‐transmiƩed   infecƟons   (TTIs)  and   the
development  of  remarkably  similar   (and  uniformly  restricƟve)   transfusion  guidelines  by  five  major  professional
socieƟes  and  the  American  AssociaƟon  of  Blood  Banks1.  These  guidelines  aim  at   reducing   the  number  of  a
patient's  allogeneic  donor  exposures  as  much  as  possible,  by  administering   transfusion  only  when  proven
(rather   than  postulated)  benefit   can  be  expected   from   the   transfusion.  Proven  benefit,  exemplified  by  a
red‐blood‐cell (RBC) transfusion to a stable and non‐bleeding patient triggered by a haemoglobin of 7 g/dL, is
based  on  findings   from  randomised  controlled  trials  (RCTs)  using  clinical  endpoints2.   In  contrast,  transfusing
stable  and  non‐bleeding paƟents  at  a haemoglobin  of  8  g/dL and  higher  is  largely  based on  postulated  benefits
based on what can be theoreƟcally deduced from pathophysiology3,4.
Adherence  to  these  restricƟve  transfusion  guidelines  consƟtutes  best  transfusion  pracƟce,  which  may  decrease
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restricƟve  transfusion  guidelines   is  that  preoperaƟve  anaemia   is  a  major  risk  factor  for  RBC  transfusion7  and,  in
addiƟon,  even  mild  preoperaƟve  anaemia   increases  perioperaƟve  mortality  and  morbidity  by  at   least  30%8.
DetecƟon  and  treatment  of  preoperaƟve  anaemia   is  thus  a  necessary  component  of  best  clinical  pracƟce.  The













It   is  all  these  strategies  together  that  represent  best  clinical  pracƟce,  according  to  the  concept  of  PaƟent  Blood





hospital,  minimising   iatrogenic  blood   losses   throughout   the   hospitalisaƟon,   using  blood‐sparing   surgical   and
anaestheƟc blood‐conservaƟon techniques, and employing perioperaƟve blood recovery and acute normovolaemic
haemodiluƟon where indicated. In this way, PBM integrates many hospital departments and services in a common







medical  paƟents20,21,23,24.  MulƟcomponent   apheresis   is  now   limited   to   collecƟng   any   combinaƟon  of  RBCs,
platelets, and/or plasma from the same donor during the same donaƟon (with at least 2 components collected from




can  reduce  their  number  of  donor  exposures  by  at  least  2‐fold,  thereby  also  reducing  the  risk  of   infecƟous  and
immunologic complicaƟons of transfusion by at least 2‐fold20,21.
Together,  PBM   and  mulƟcomponent   apheresis   represent   a  new  paradigm   –the  paƟent‐centric  paradigm–  of
transfusion   medicine   that   will   hopefully   replace   the   current   (component‐centric)   paradigm   in   the   21st
century20,21,25. Whereas now each blood component is a drug to be dispensed, in the future we will hopefully be
meeƟng  each  paƟent's  transfusion  needs  through  an   individualised  combinaƟon  of   (PBM  and  mulƟcomponent‐
apheresis)  approaches.  Whereas  our  current  focus   is  on  the  quality  of  the  component,   in  the  future  we  should
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